Core Viewpoint - Antu Biology (603658.SH) announced that its wholly-owned subsidiary, Zhengzhou Sikun Biological Engineering Co., Ltd., and its secondary subsidiary, Zhengzhou Matris Biological Technology Co., Ltd., have recently received the "High-tech Enterprise Certificate" from the Henan Provincial Department of Science and Technology, Henan Provincial Department of Finance, and the State Taxation Administration of Henan Province, marking their recognition as high-tech enterprises [1] Group 1 - The subsidiaries received their high-tech enterprise certifications for the first time [1] - The certificate numbers are GR202541001506 and GR202541001407, with both issued on November 4, 2025, and valid for three years [1]

Group 1: Industry Overview - The global robotics and embodied intelligence industry is experiencing significant growth, with companies like Zhiyuan Innovation and Shenzhen Zhongqing Robotics establishing manufacturing bases in Zhengzhou to enhance the AI ecosystem [1] - Zhengzhou aims to become a national hub for AI innovation, with a clear strategic plan that includes building 10 innovation platforms and achieving a scale of 350 billion yuan for core AI industries by the end of 2025 [2][3] Group 2: Technological Advancements - Zhengzhou is focusing on key areas such as large models, intelligent robotics, and autonomous driving, collaborating with leading enterprises to support vertical model development and technology transfer [3] - AI is transforming manufacturing paradigms, as seen with China Railway Industry's launch of an industry-specific large model that enhances decision-making and quality control in production [4][5] Group 3: Applications in Various Sectors - In the mining sector, AI technologies from companies like Hengda Zhikong are improving safety and efficiency, achieving a 15% increase in production capacity and generating an additional 1.5 billion yuan in revenue [5] - In healthcare, AI is enhancing diagnostic accuracy and operational efficiency, with companies like Antu Bio and Anjielai Technology developing advanced AI systems for clinical decision support and rehabilitation [5][6] Group 4: Infrastructure and Talent Development - Zhengzhou is establishing itself as a leader in computing power infrastructure, with companies like Super Fusion Digital Technology providing robust services to over 5000 partners globally [7] - The city is fostering talent through innovative education models that integrate industry and academia, preparing students for careers in robotics and AI [8]

□本报记者 陈浩 祁道鹏 新年伊始，中原大地重点项目建设热潮涌动，国内最大的体外诊断产业园在郑州经开区加速成型。 1月13日，记者走进安图生物体外诊断产业园三期项目建设现场，热火朝天的施工场景扑面而来：主体 建筑全部竣工，内部装修紧张推进，部分员工已抢先入驻办公。 安图生物专注于体外诊断试剂和仪器的研发、制造、整合及服务，产品覆盖免疫、微生物、生化等全检 测领域，更在测序、质谱等精准诊断赛道抢先布局。截至目前，该公司产品已进驻全国2600多家三级医 院，覆盖率达64.8%；二级及以上医院终端用户超6700家，产品还远销全球100多个国家和地区，稳稳 跻身国内行业第一梯队。 在安图生物仪器生产中心，自动化流水线高速运转，机械臂精准操作，技术工人轻点屏幕，全流程数据 一目了然。"核心技术攥在自己手里，要让中国智造惠及更多患者！"张瑞峰语气坚定。 作为国内第一家在上交所主板上市的体外诊断领域研发制造型企业，安图生物连续多年研发高投入，既 啃下了技术攻关的"硬骨头"，又收获了产业升级的"甜果实"。 "十四五"期间，安图生物研发投入累计超30亿元，研发费用占比连续多年超14%，研发强度稳居行业第 一梯队。目前，公司拥有 ...

证券代码：603658 证券简称：安图生物 公告编号：2026-001 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行及拟履行的审议程序 郑州安图生物工程股份有限公司（以下简称"公司"）于 2025 年 12 月 9 日召开第五届董事会第九次会议，审议通过了《关于使用闲置募集资金进行 现金管理的议案》，同意公司在确保不影响募集资金项目建设和募集资金使 用的情况下，公司拟分别使用不超过 1.4 亿元公开发行可转换公司债券闲置 募集资金和不超过 15.4 亿元非公开发行股票闲置募集资金进行现金管理，分 别用于购买产品期限或剩余期限不超过 12 个月的结构性存款、大额存单、 国债逆回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型 产品。在上述额度范围内，资金可在 12 个月内滚动使用。具体内容详见公 司于 2025 年 12 月 10 日在上海证券交易所网站（www.sse.com.cn）披露的《安 图生物关于使用闲 ...

Core Insights - The article discusses the significant breakthroughs in mass spectrometry products released in 2025, highlighting the technological advancements and market trends that shape the industry [1] Group 1: Import Market Developments - In 2025, 15 new mass spectrometry products were launched by import manufacturers, including various types such as Orbitrap, Q-TOF, and triple quadrupole systems [2] - Key players like PerkinElmer, Thermo Fisher, Bruker, Waters, SCIEX, and Agilent released multiple high-impact products, showcasing trends towards higher sensitivity, smarter data collection, and broader application coverage [2][3] - The focus of technological innovation has shifted from optimizing single performance parameters to a comprehensive breakthrough in software and hardware collaboration, application processes, and data systems [3] Group 2: Domestic Market Developments - In 2025, domestic manufacturers launched 20 new mass spectrometry products, with triple quadrupole systems accounting for 50% of the releases, emphasizing real-world application scenarios [7][8] - Notable products include the TQ9200 series from Anhui Wanyi and the YS iFAS from Shandong Yingsheng, both of which are designed for clinical applications [8] - The trend in domestic products is towards automation and standardization in clinical testing, providing essential support for widespread clinical applications [9] Group 3: Technological Innovations - Shimadzu's LCMS-8065XE integrates innovative technology with energy-saving features, reducing power consumption by approximately 31% [4][5] - Waters introduced the Xevo charge detection mass spectrometer (CDMS), enhancing capabilities for measuring large biomolecules, which is crucial for next-generation therapeutics and vaccine development [5] - The emergence of products like the CANRE-120 from Huayi Ningchuang and the CRAIV-2110 from Huayi Ningchuang reflects a focus on rapid response and flexibility in various application scenarios [9][10] Group 4: Market Trends and Future Directions - The mass spectrometry industry is increasingly addressing the question of how to effectively serve research, clinical, and industrial needs, moving beyond just performance metrics [11] - The competitive landscape is shifting towards a complete technological ecosystem and application maturity rather than just individual instrument performance [5][11]

Core Viewpoint - Antu Biology's stock performance shows a slight increase, with a trading volume of 1.11 billion yuan and a net financing buy of 640,600 yuan on January 6, indicating low financing levels compared to historical data [1] Financing Summary - On January 6, Antu Biology had a financing buy of 13.26 million yuan and a financing repayment of 12.62 million yuan, resulting in a net financing buy of 640,600 yuan [1] - The total financing and securities lending balance for Antu Biology reached 463 million yuan, with the financing balance at 459 million yuan, accounting for 2.21% of the circulating market value, which is below the 10th percentile of the past year [1] - The securities lending data shows a repayment of 700 shares and a sale of 600 shares, with a total sale amount of 21,800 yuan, and a securities lending balance of 3.99 million yuan, also below the 50th percentile of the past year [1] Company Performance Summary - As of September 30, Antu Biology had 34,000 shareholders, a decrease of 0.58% from the previous period, with an average of 16,816 circulating shares per shareholder, an increase of 0.58% [2] - For the period from January to September 2025, Antu Biology reported a revenue of 3.13 billion yuan, a year-on-year decrease of 7.48%, and a net profit attributable to shareholders of 860 million yuan, down 10.11% year-on-year [2] - Since its A-share listing, Antu Biology has distributed a total of 4.05 billion yuan in dividends, with 1.79 billion yuan distributed over the past three years [2] Shareholder Structure Summary - As of September 30, 2025, the top ten circulating shareholders of Antu Biology include Zhonggeng Value Pioneer Stock, holding 7.84 million shares, a decrease of 1.42 million shares from the previous period [2] - Hong Kong Central Clearing Limited is the fourth largest shareholder with 7.15 million shares, an increase of 421,430 shares [2] - Other notable changes include a decrease in holdings by Huabao Zhongzheng Medical ETF and an increase in holdings by Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A [2]

Group 1 - The Zhengzhou Municipal Economic Work Conference emphasizes the "1+7+7+7" work deployment to ensure a strong start for the "14th Five-Year Plan" and high-quality economic development [1][4][5] - Companies in Zhengzhou express encouragement and commitment to align their actions with the conference's directives, focusing on innovation and digital transformation [2][3][6] - The conference highlights the importance of optimizing the business environment, enhancing innovation, and expanding industrial investment to support enterprise development [2][4] Group 2 - Super Fusion Digital Technology Co., Ltd. identifies AI, data, computing power, energy, materials, and biotechnology as core technological factors driving global changes over the next 10-20 years [1] - The company aims to leverage opportunities in computing power, AI, and liquid cooling to develop leading products and solutions, facilitating the application of AI in various industries [1] - AnTuo Bioengineering Co., Ltd. plans to increase R&D investment and focus on key technologies like nucleic acid sequencing and mass spectrometry to upgrade products towards precision diagnostics [3] Group 3 - Zhengzhou Public Utilities Group commits to implementing the conference's spirit by enhancing service capabilities and promoting green transformation across various sectors [4] - The group aims to improve quality and efficiency through technological innovation and digital empowerment, contributing to the city's high-quality development [4] - Zhengzhou Construction Group focuses on participating in urban renewal and infrastructure projects while promoting intelligent and green construction practices [5]

郑州安图生物工程股份有限公司 关于全资子公司及二级子公司通过高新技术企业 重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）全资子公司郑州伊美诺 生物技术有限公司（以下简称"伊美诺"）、二级子公司郑州标源生物科技有限公 司（以下简称"郑州标源"）于近日收到河南省科学技术厅、河南省财政厅、国家 税务总局河南省税务局联合颁发的《高新技术企业证书》，被认定为高新技术企 业。证书编号分别为：GR202541002114、GR202541001628，发证日期均为 2025 年 11 月 4 日，有效期均为三年。 本次系上述子公司原高新技术企业证书有效期满后进行的重新认定，根据国 家有关规定，上述子公司自通过高新技术企业重新认定起连续三年（2025 年至 2027 年）可继续享受国家关于高新技术企业的税收优惠政策，即按 15%的税率 缴纳企业所得税。 2025 年度子公司伊美诺、郑州标源已按照 15%的企业所得税税率进行纳税 申报及预缴，因此本次取得高新技术企业证书不影响公司 ...

Core Viewpoint - Antu Biology (603658.SH) has received the "High-tech Enterprise Certificate" for its wholly-owned subsidiary Zhengzhou Yimeno Biotechnology Co., Ltd. and its secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. This recognition allows the subsidiaries to benefit from tax incentives for three years from 2025 to 2027 [1] Group 1 - The subsidiaries were re-certified as high-tech enterprises after the expiration of their previous certificates [1] - The certificate numbers are GR202541002114 and GR202541001628, with an issuance date of November 4, 2025, and a validity period of three years [1] - The subsidiaries will enjoy a corporate income tax rate of 15% as part of the national tax incentives for high-tech enterprises [1]

Group 1 - Company Antu Biology (603658.SH) announced that its wholly-owned subsidiary Zhengzhou Yimeinuo Biotechnology Co., Ltd. and its secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. have recently received the "High-tech Enterprise Certificate" from the Henan Provincial Department of Science and Technology, Henan Provincial Department of Finance, and the State Taxation Administration of Henan Province [1] - The certificate numbers are GR202541002114 and GR202541001628, with both issued on November 4, 2025, and valid for three years [1] - This recognition is a renewal of the previous high-tech enterprise certification, allowing the subsidiaries to continue enjoying tax benefits under the national policy for high-tech enterprises, specifically a corporate income tax rate of 15% from 2025 to 2027 [1]